Scientific publications

Scientific articles authored by Novo Nordisk

The information you can search here is retrieved via the database Current Contents®, covering 95% of publications within the life science area. Only articles authored by at least one researcher from Novo Nordisk are included in the search results. The database provides easy access to tables of contents, abstracts, bibliographic information, and abstracts from the most recently published issues of leading scholarly journals.

46 results found.
Showing results 1-20
PreviousPrevious 1 2 3 NextNext
Journal Author Year
Diabetes Research and Clinical Practice

Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial

Kaneko S ; Chow F ; Choi DS ; Taneda S ; Hirao K ; Park Y ; Andersen TH ; Gall MA ; Christiansen JS 2015
Clinical Drug Investigation

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region

Nosek L ; Coester HV ; Roepstorff C ; Thomsen HF ; Kristensen NR ; Haahr H ; Heise T 2014
Clinical Drug Investigation

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment

Kupcova V ; Arold G ; Roepstorff C ; Hojbjerre M ; Klim S ; Haahr H 2014
Clinical Pharmacokinetics

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment

Kiss I ; Arold G ; Roepstorff C ; Bottcher SG ; Klim S ; Haahr H 2014
Clinical Pharmacokinetics

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

Haahr H ; Heise T 2014
Clinical Therapeutics

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

Hompesch M ; Morrow L ; Watkins E ; Roepstorff C ; Thomsen HF ; Haahr H 2014
Diabetes Care

Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

Fulcher GR ; Christiansen JS ; Bantwal G ; Polaszewska-Muszynska M ; Mersebach H ; Andersen TH ; Niskanen LK 2014
Diabetes Care

Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

Buse JB ; Vilsboll T ; Thurman J ; Blevins TC ; Langbakke IH ; Bottcher SG ; Rodbard HW 2014
Diabetes Obesity and Metabolism

Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial

Davies MJ ; Gross JL ; Ono Y ; Sasaki T ; Bantwal G ; Gall MA ; Niemeyer M ; Seino H 2014
Diabetes Obesity and Metabolism

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naive patients with type 2 diabetes

Rodbard HW ; Cariou B ; Zinman B ; Handelsman Y ; Wolden ML ; Rana A ; Mathieu C 2014
Diabetes Obesity and Metabolism

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

Mathieu C ; Rodbard HW ; Cariou B ; Handelsman Y ; Philis-Tsimikas A ; Francisco AMO ; Rana A ; Zinman B 2014
Diabetes Obesity and Metabolism

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Evans M ; Wolden M ; Gundgaard J ; Chubb B ; Christensen T 2014

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study

Koehler G ; Heller S ; Korsatko S ; Roepstorff C ; Rasmussen S ; Haahr H ; Pieber TR 2014
Drugs and Aging

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus

Korsatko S ; Deller S ; Mader JK ; Glettler K ; Koehler G ; Treiber G ; Urschitz M ; Wolf M ; Hastrup H ; Sondergaard F ; Haahr H ; Pieber TR 2014
Endocrine Practice


Rodbard HW ; Gough S ; Lane W ; Korsholm L ; Bretler DM ; Handelsman Y 2014
Expert Opinion on Drug Delivery

Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals

Pfutzner A ; Forst T ; Niemeyer M ; Bailey T 2014
Lancet Diabetes and Endocrinology

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

Gough SCL ; Bode B ; Woo V ; Rodbard HW ; Linjawi S ; Poulsen P ; Damgaard LH ; Buse JB 2014
Pediatric Diabetes

Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes

Biester T ; Blaesig S ; Remus K ; Aschemeier B ; Kordonouri O ; Granhall C ; Sondergaard F ; Kristensen NR ; Haahr H ; Danne T 2014
Advances in Therapy

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)

Philis-Tsimikas A ; Brod M ; Niemeyer M ; Francisco AMO ; Rothman J 2013

Ligand-Controlled Assembly of Hexamers, Dihexamers, and Linear Multihexamer Structures by the Engineered Acylated Insulin Degludec

Steensgaard DB ; Schluckebier G ; Strauss HM ; Norrman M ; Thomsen JK ; Friderichsen AV ; Havelund S ; Jonassen I 2013